SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 16th, 2015 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of March 9, 2015, by and between RICH PHARMACEUTICALS, INC., a Nevada corporation, with headquarters located at 9595 Wilshire Blvd., Suite 900, Beverly Hills, CA 90212 (the "Company"), and AUCTUS PRIVATE EQUITY FUND, LLC, a Delaware limited liability company, with its address at 101 Arch Street, 20th Floor, Boston, MA 02110 (the "Buyer").
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 4th, 2016 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 20, 2016, by and between Rich Pharmaceuticals, Inc., a Nevada corporation, with headquarters located at 9595 Wilshire Blvd Suite 900, Beverly Hills, CA 90212 (the “Company”), and LG Capital Funding, LLC., a New York Limited Liability Company, with its address at 1218 Union Street, Suite #2, Brooklyn, NY 11225 (the “Buyer”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 27th, 2017 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
This REGISTRATION RIGHTS AGREEMENT (the “Agreement”), dated as of February 22, 2017 (the “Execution Date”), is entered into by and between Rich Pharmaceuticals, Inc., a Nevada corporation with its principal executive office at 9595 Wilshire Boulevard, Suite 900, Beverly Hills, CA 90212 (the “Company”), and GHS Investments LLC, a Nevada limited liability company, with offices at 200 Stonehinge Lane, Suite 3, Carle Place, NY 11514. (the “Investor”).
AMENDED AND RESTATED INVESTMENT AGREEMENTInvestment Agreement • June 11th, 2015 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED INVESTMENT AGREEMENT (the “Agreement”), dated as of June, 10, 2015 (the “Execution Date”), is entered into by and between Rich Pharmaceuticals, Inc., a Nevada corporation (the “Company”), with its principal executive office at 9595 Wilshire Blvd, Suite 900, Beverly Hills, CA 90212, and LG Capital Funding, LLC, a New York limited liability company (the “Investor”), with its principal executive office at 1218 Union Street, Suite #2, Brooklyn, NY 11225.
EQUITY FINANCING AGREEMENTEquity Financing Agreement • February 27th, 2017 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
This EQUITY FINANCING AGREEMENT (the “Agreement”), dated as of February 22, 2017 (the “Execution Date”), is entered into by and between Rich Pharmaceuticals, Inc., a Nevada corporation with its principal executive office at 9595 Wilshire Boulevard, Suite 900 Beverly Hills, CA 90212 (the “Company”), and GHS Investments LLC, a Nevada limited liability company, with offices at 200 Stonehinge Lane, Suite 3, Carle Place, NY 11514. (the “Investor”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 23rd, 2018 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
THIS PURCHASE AGREEMENT (“Agreement”) is made as of the 15th day of March, 2018 by and between Rich Pharmaceuticals, Inc., (the “Company”), and GHS Investments, LLC (the “Investor”).
ContractRich Pharmaceuticals, Inc. • June 29th, 2016 • Pharmaceutical preparations
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. LENDERS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
ContractRich Pharmaceuticals, Inc. • November 14th, 2014 • Pharmaceutical preparations • Texas
NEITHER THIS NOTE NOR THE SECURITIES THAT MAY BE ISSUED BY THE BORROWER UPON CONVERSION HEREOF (COLLECTIVELY, THE “SECURITIES”) HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THE SECURITIES NOR ANY INTEREST OR PARTICIPATION THEREIN MAY BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (I) IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE 1933 ACT, OR APPLICABLE STATE SECURITIES LAWS; OR (II) IN THE ABSENCE OF AN OPINION OF COUNSEL, IN A FORM ACCEPTABLE TO THE ISSUER, THAT REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT OR; (III) UNLESS SOLD, TRANSFERRED OR ASSIGNED PURSUANT TO RULE 144 UNDER THE 1933 ACT.
Security AgreementSecurity Agreement • June 2nd, 2015 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • Utah
This Security Agreement (this “Agreement”), dated as of May 27, 2015, is executed by Rich Pharmaceuticals, Inc., a Nevada corporation (“Debtor”), in favor of Typenex Co-Investment, LLC, a Utah limited liability company (“Secured Party”).
AGREEMENT OF CONVEYANCE, TRANSFER AND ASSIGNMENT OF ASSETS AND ASSUMPTION OF OBLIGATIONSAgreement • July 24th, 2013 • Nepia Inc. • Heating equip, except elec & warm air; & plumbing fixtures • Nevada
This Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (“Transfer and Assumption Agreement”) is made as of July 19, 2013, by Nepia, Inc., a Nevada corporation (“Assignor”), and Li Deng Ke and Xiong Chao Jun (together “Assignee”).
ASSIGNMENT AGREEMENTAssignment Agreement • October 8th, 2014 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
This ASSIGNMENT AGREEMENT (“Agreement”) is entered into as of October 6, 2014 (the “Effective Date”) by and between Rich Pharmaceuticals, Inc., a Nevada Corporation (the “Company”), Richard L. Chang Holding’s, LLC (“Holdings LLC”), and Imagic LLC, a California limited liability company (“Imagic LLC”).
RICH PHARMACEUTICALS, INC.Nonstatutory Stock Option Agreement • August 29th, 2014 • Rich Pharmaceuticals, Inc. • Heating equip, except elec & warm air; & plumbing fixtures
Rich Pharmaceuticals, Inc., a Nevada corporation (the "Company"), hereby grants an Option to purchase shares of its common stock (the "Shares") to the Optionee named below. The terms and conditions of the Option are set forth in this cover sheet, in the attachment and in the Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "Plan").
EMPLOYMENT AGREEMENTEmployment Agreement • September 12th, 2013 • Rich Pharmaceuticals, Inc. • Heating equip, except elec & warm air; & plumbing fixtures • California
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of September 6, 2013 by and between Rich Pharmaceuticals, Inc., a Nevada corporation (the “Company”) and Ben Chang (the “Employee”).
COLLABORATION AGREEMENTCollaboration Agreement • March 21st, 2017 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
This Collaboration Agreement ("Agreement") is entered into effective as of March 20, 2017 (the "Effective Date") by and between Rich Pharmaceuticals, Inc, a Nevada corporation ("RPI"), and I Tech Health Corp., a Delaware corporation ("ITech"), with reference to the following:
WAIVER TO MEMORANDUM OF UNDERSTANDING AND ASSET ASSIGNMENT AGREEMENTAnd Asset Assignment Agreement • January 17th, 2014 • Rich Pharmaceuticals, Inc. • Heating equip, except elec & warm air; & plumbing fixtures
Whereas, , Rich Pharmaceuticals, Inc., a Nevada corporation (the “Company”), Imagic, LLC (“Imagic”), and Richard L. Chang Holding's, LLC (“Holdings LLC”) entered into a Memorandum of Understanding and Asset Assignment Agreement dated as of July 16, 2013 (the “Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 10th, 2015 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of Aug 4, 2015 by and between Rich Pharmaceuticals, Inc., a Nevada corporation (the “Company”) and Richard Salvador (the “Employee”).
DEBT PURCHASE AGREEMENTDebt Purchase Agreement • February 27th, 2017 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Debt Purchase Agreement (the “Agreement”) made as of this _17th day of February, 2017 by and between LG Capital Funding, LLC (the “Seller”) and GHS Investments, LLC (the “Buyer”).
ASSET ASSIGNMENT AGREEMENTAsset Assignment Agreement • July 3rd, 2019 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • Wyoming
This Asset Assignment Agreement (“Agreement”) is entered into as of June 11, 2019 (the “Effective Date”) by and among Richard L. Chang Holding's, LLC, a Nevada limited liability company (“Holdings LLC”), and Rich Pharmaceuticals, Inc. a Wyoming corporation (“RICH”).
MEMORANDUM OF UNDERSTANDING AND ASSET ASSIGNMENT AGREEMENTAnd Asset Assignment Agreement • July 24th, 2013 • Nepia Inc. • Heating equip, except elec & warm air; & plumbing fixtures • Nevada
This Memorandum of Understanding and Asset Assignment Agreement (“Agreement”) is entered into as of July 18, 2013 (the “Effective Date”) by and among Nepia, Inc., a Nevada corporation (“NEPIA”), Rich Pharmaceuticals, Inc. (the “Rich”), and Richard L. Chang Holding's, LLC (“Holdings LLC”).
ContractRich Pharmaceuticals, Inc. • June 2nd, 2015 • Pharmaceutical preparations • Utah
THIS NOTE MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE ALIENATED OR ENCUMBERED WITHOUT THE PRIOR WRITTEN CONSENT OF INVESTOR.
ContractRich Pharmaceuticals, Inc. • August 18th, 2014 • Heating equip, except elec & warm air; & plumbing fixtures • California
NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
SUPPORT AND COLLABORATION AGREEMENTSupport and Collaboration Agreement • July 12th, 2017 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
This Support and Collaboration Agreement (the “Agreement”) is effective as of July 11, 2017 ("Effective Date") by and between Rich Pharmaceuticals, Inc., a Nevada corporation (“Rich”), and Mega Bridge, Inc., a Nevada corporation, to be renamed “Hypgen” (“Hypgen”).
Securities Purchase AgreementSecurities Purchase Agreement • June 2nd, 2015 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • Utah
This Securities Purchase Agreement (this “Agreement”), dated as of May 27, 2015, is entered into by and between Rich Pharmaceuticals, Inc., a Nevada corporation (“Company”), and Typenex Co-Investment, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”).
ASSET LICENSING AGREEMENTAsset Licensing Agreement • July 3rd, 2019 • Rich Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Asset Assignment Agreement (“Agreement”) is entered into as of June 11, 2019 (the “Effective Date”) by and among Rich Pharmaceuticals Inc., a Wyoming corporation (“RICH”), and Geopulse Corporation, Inc., a Nevada corporation (“COMPANY”).
